Cytokinetics (NASDAQ:CYTK) Stock Price Down 6.6% – Time to Sell?

Cytokinetics, Incorporated (NASDAQ:CYTK)’s stock price traded down 6.6% during trading on Friday . The stock traded as low as $76.40 and last traded at $75.97. Approximately 1,067,949 shares traded hands during trading, a decline of 51% from the average session volume of 2,162,348 shares. The stock had previously closed at $81.37.

Key Headlines Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Myqorzo uptake is encouraging. Management and analysts highlighted strong early traction for Myqorzo, supporting the view that the drug could become an important commercial growth driver. CYTK Q2 Earnings Top Estimates, Myqorzo Uptake Strong
• Positive Sentiment: Quarterly results exceeded expectations. Cytokinetics reported revenue of $28.6 million versus consensus estimates near $17.6 million and a loss of $1.50 per share, narrower than the expected $1.63 loss. Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
• Positive Sentiment: Analysts raised their targets. Needham increased its target from $102 to $112 and maintained a “buy” rating, while Citizens JMP raised its target from $105 to $110 and kept a “market outperform” rating. These actions indicate analysts see meaningful upside if the launch continues to perform. Analyst Price Target Updates
• Neutral Sentiment: The commercial launch is still early. RBC viewed the earnings beat as supportive of Myqorzo’s launch, but investors will likely focus on prescription growth, reimbursement and the pace at which sales offset launch expenses.
• Negative Sentiment: Profitability and cash flow remain major concerns. Revenue fell 57.1% year over year, while Cytokinetics posted a $179.2 million operating loss and used $159.8 million in operating cash during the quarter. Higher launch costs and the absence of milestone payments also weighed on results, despite the $1.17 billion cash balance. Cytokinetics Q2 2026 Earnings: Revenue Beats but Losses Persist
• Negative Sentiment: Reported losses widened from the prior-year quarter. The quarterly loss increased from $1.12 per share a year earlier to $1.50, underscoring that CYTK remains dependent on successful commercialization and future financing or milestone opportunities. Cytokinetics Reports Q2 Loss, Beats Revenue Estimates

Analysts Set New Price Targets

Several research firms recently issued reports on CYTK. Wells Fargo & Company raised their target price on Cytokinetics from $95.00 to $105.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Needham & Company LLC boosted their price target on Cytokinetics from $102.00 to $112.00 and gave the company a “buy” rating in a research note on Friday. HC Wainwright increased their price objective on Cytokinetics from $136.00 to $140.00 and gave the company a “buy” rating in a report on Monday, May 11th. Morgan Stanley raised their price objective on Cytokinetics from $90.00 to $103.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Finally, Mizuho lifted their target price on Cytokinetics from $100.00 to $118.00 and gave the stock an “outperform” rating in a report on Wednesday, June 24th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $100.85.

Cytokinetics Stock Performance

The stock has a 50 day simple moving average of $78.91 and a two-hundred day simple moving average of $70.90. The firm has a market cap of $9.55 billion, a PE ratio of -10.63 and a beta of 0.38.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.63) by $0.13. The company had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same period last year, the firm earned ($1.12) EPS. The business’s quarterly revenue was down 57.1% compared to the same quarter last year. Equities research analysts forecast that Cytokinetics, Incorporated will post -6.2 earnings per share for the current year.

Insider Buying and Selling at Cytokinetics

In other news, Director B Lynne Parshall sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $74.08, for a total transaction of $370,400.00. Following the sale, the director owned 15,784 shares of the company’s stock, valued at $1,169,278.72. This trade represents a 24.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,000 shares of Cytokinetics stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $74.08, for a total transaction of $1,111,200.00. Following the transaction, the executive vice president directly owned 58,555 shares of the company’s stock, valued at approximately $4,337,754.40. This trade represents a 20.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 115,179 shares of company stock valued at $9,126,054. 2.60% of the stock is owned by company insiders.

Institutional Trading of Cytokinetics

A number of hedge funds have recently added to or reduced their stakes in CYTK. Kemnay Advisory Services Inc. acquired a new stake in Cytokinetics during the fourth quarter valued at $27,000. Kestra Advisory Services LLC acquired a new position in shares of Cytokinetics in the fourth quarter worth about $29,000. TD Waterhouse Canada Inc. acquired a new position in shares of Cytokinetics in the fourth quarter worth about $32,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Cytokinetics by 46.0% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 543 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 171 shares in the last quarter. Finally, Quarry LP purchased a new stake in shares of Cytokinetics during the 3rd quarter worth about $30,000.

About Cytokinetics

Cytokinetics, Inc is a late?stage biopharmaceutical company focused on the discovery and development of novel small?molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.